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With the introduction of highly active antiretroviral therapy, a number of drugs have been developed. The best
choice concerning which antiretroviral analogs to start is always under discussion, especially in the choice between
non-nucleoside reverse transcriptase inhibitors-based therapies and ritonavir-boosted protease inhibitors. Both are
proven to control viral replication and lead to immunological gain. The choice between a non-nucleoside analog
reverse transcriptase inhibitor and a protease inhibitor as a third antiretroviral drug in the therapy should consider
factors related to the individual, as well as the inclusion of the best therapy in the patient’s daily activities and
potential adherence. The protease inhibitor-based therapies showed similar efficacy among the various inhibitors
with characteristics concerning the adverse events from each medicine. For the treatment of protease-resistant
patients, darunavir and tipranavir showed good efficacy with higher genetic barrier to resistance.
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Since 1996, with the introduction of highly active
antiretroviral (ARV) therapy (HAART), a number of drugs
have been developed. The best choice concerning which
antiretroviral drugs to start is always under discussion,
especially in the choice between non-nucleoside analog
reverse transcriptase inhibitors (NNRTI)-based therapies and
ritonavir-boosted protease inhibitors (PI/r). Both are proven
to control viral replication and lead to immunological gain [1].
Different recommendations, based on national [2] and
international [3-5] guidelines, indicate first choice and alternative
drugs, in case of impossibility to use the preferable ones.
The choice between an NNRTI or a PI/r as the third
antiretroviral drug in the therapy should consider factors
related to the individual, such as: neuropsychiatric diseases,
family planning (in case o female patients), cardiovascular risk
(dyslipidemia and resistance to insulin), liver diseases, drug-
drug interaction, as well as the inclusion of the best therapy in
the patient’s daily activity and potential adherence.
The Brazilian consensus for the treatment of HIV-infected adults
and adolescents [2], recommends two NRTIs (zidovudine and
lamivudine) in association with efavirenz or lopinavir/r. Among
the alternative therapies associated with NRTI, it is possible to
choose nevirapine or atazanavir/r (Table 1).
Currently, lopinavir/r represents the comparator PI in most
of the large studies with new PI/r, in determining efficacy. It is
an ARV with proven long-term efficacy [6], the only PI co-
formulated with ritonavir, representing a great advantage in
terms of adherence and guarantee of use for ritonavir but, on
the other hand, it does not allow a dose reduction of the latest
in case of intolerance or metabolic changes.
Among the international guidelines, as recommended by
the US Department of Health-DHHS, when it is decided to use
a PI/r, the choice can be done between lopinavir/ritonavir (LPV/
r) once or twice daily, atazanavir/ritonavir (ATV/r) once daily,
fosamprenavir/ritonavir twice daily and, most recently
incorporated, darunavir/ritonavir (DRV/r) once daily. The latest,
based on the ARTEMIS [7] study results, demonstrated DRV/
r non-inferiority compared to LPV/r, in antiretroviral therapy
naïve patients over 48 weeks, and to be superior to LPV/r in 96
weeks follow-up. On the other hand, the International AIDS
Society (IAS) [4] recommendation also includes the use of
saquinavir/ritonavir (SQV/r) as the preference PI/r (Table 2).
Factors to Be Considered When Choosing a PI/r in Initial
Therapy
All the protease inhibitors, except nelfinavir, should be
administered with ritonavir. The coadministration increases
the PI serum level, extending the dose intervals, facilitating
the dosage, decreasing the number of tablets and increasing
the strength, inclusively against strains with decreased
sensitivity to PI [8,9]. The clinical trials with PI/r showed they
are comparable concerning the virological, immune responses
and development of resistance [7,10-13].
CASTLE Study: Atazanavir/r versus Lopinavir/r [10]
The CASTLE study showed the non-inferiority of ATV/r
(300/100 mg, once daily) versus LPV/r (400/100 mg twice daily)
combined with tenofovir/emtricitabine (TDF/FTC), in 883 naïve
patients randomized at 1:1 to each group after 48 weeks. In the
96-week analysis ATV/r has shown to be superior to LPVr
(Figure 1). However, ATV/r has shown better tolerability and
lower incidence of discontinuation related to adverse events,
what can have influenced the intention to treat analysis [14].
Table 1. Preferable and alternative recommendations from the
Brazilian Consensus for ARV treatment.
First Choice Alternative
2 NRTI AZT/3TC ddI EC/3TC
TDF/3TC
NNRTI Efavirenz Nevirapine
PI Lopinavir/r Atazanavir/r
ddI EC: didanisone “enteric coat” (slow release tablets).
TDF: tenofovir.
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Hyperbilirubinemia was most common in patients using ATV/
r, and events related to the gastrointestinal (GI) tract,
hypertriglyceridemia, hypercholesterolemia (including
increased LDL) and the use of hypolipemiant agents was
higher in patients using LPV/r (Figure 2).
Atazanavir should be used with caution when combined
with antiacids and H2 blockers. The advantages of using
atazanavir are good gastrointestinal tolerance, the lower
number of tablets and the once daily use, improving adherence.
It should be preferably administered with food.
KLEAN Study [11]: Fosamprenavir/r versus Lopinavir/r
The association FPV/r (700/100 mg twice daily) showed to
be non-inferior when compared with LPV/r (400/100 mg twice
daily), in combination with abacavir/lamivudine (ABC/3TC)
in 878 antiretroviral therapy naïve patients, in 144 weeks
(Figure 3). The tolerability and incidence of adverse events
were similar between the groups.
In a retrospective study, Calza et. al. showed that
fosamprenavir/ritonavir (700/100 mg twice daily) has similar
efficacy in virological and immune responses when compared
to lopinavir/ritonavir at the usual dose, both associated with
two NRTIs, but with lower incidence of diarrhea and
hypertriglyceridemia when fosamprenavir/ritonavir was used
as the third drug in ARV therapy (p=0,006 and p=0,008,
respectively) [15].
ALERT Study [12]: Fosamprenavir/r versus Atazanavir/r
In this study, 106 naïve patients were randomized to receive
FPV/r (1400/100 mg once daily) or ATV/r (300/100 mg once
daily) associated with TDF/FTC. The virological response in
48 weeks was similar between the groups. Adverse events
were more common in patients using ATV/r, especially due to
hyperbilirubinemia. Lipid changes were similar between the
groups (Figures 4 and 5).
FPV/r has the advantage of being administered once or
twice daily, without food restriction. In association with 100
mg RTV once daily, it seems to have a better metabolic profile,
when compared with 200 mg/day RTV [16].
The use of FPV/r (1400/100 mg once daily) was approved
by FDA; however, it remains as an alternative recommendation
by DHHS, probably, due to the existence of few studies
validating this dose.
GEMINI Study [13]: Saquinavir/ritonavir versus Lopinavir/
Ritonavir
This study compared the use of SQV/r (1000/100 mg twice
daily) and LPV/r (400/100 mg twice daily) in 337 antiretroviral
therapy naïve patients, and showed the non-inferiority of SQV/
r compared to LPV/r (Figure 6). SQV/r was associated with a
lower increase in triglycerides, total cholesterol (but not
concerning LDL) and similar occurrence of other adverse events.
However, the significant amount of tablets (10 tablet/day SQV)
makes the use of this drug inconvenient compared to other PIs.
ARTEMIS Study [6]: Darunavir/Ritonavir versus Lopinavir/
Ritonavir
In this study, involving 689 individuals, DRV/r (800/100 mg
once daily) showed to be non-inferior when compared to LPV/
r (400/100 mg once daily or 800/200 mg once daily), after 48
weeks of treatment, in ARV treatment naïve patients. DRV/r was
superior in the subgroup with viral load (VL) higher than 100,000
copies/mL. The 96-week analysis also showed that DRV/r is
superior for patients with VL lower than 50 copies/mL, being
this difference caused, especially, by the lower virological failure
in this group. DRV/r showed lower incidence of adverse events
related to GI tract and lower lipid changes (Figures 7 and 8).
Antiretroviral Treatment in Patients with Resistance to
Multiple Drugs
In patients multi-experienced with PIs, the shift to another
ARV therapy should be oriented by genotype and should
contain a ritonavir-boosted protease inhibitor, even with
protease resistance [2]. The decreased PI activity, as well as
with NRTIs, is not complete, even in the presence of resistance
mutations, due to the residual effect that these drugs still
maintain [17,18].
Darunavir and tipranavir are non-peptide protease
inhibitors, with increased affinity to the active protease site,
with bindings through stronger hydrogen bridges [19,20]. In
vitro studies evidenced that the resistance to darunavir was
developed on a slower way compared with other PIs.
The POWER studies [21] showed the efficacy of using
darunavir/r in patients with antiretroviral experience in three
classes and documented resistance in protease. In this study,
255 patients were randomized at a 1:1 ratio to receive darunavir/
r (600/100 mg twice daily) or a PI/r as a comparator, chosen by
Table 2. Comparison between DHHS, IAS and EACS guidelines.
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Antiretroviral Drug DHHS3 IAS-USA4 EACS5
NRTI Tenofovir/Emtricitabine Abacavir/Lamivudine Abacavir/Lamivudine
Tenofovir/Emtricitabine Tenofovir/Emtricitabine
NNRTI Efavirenz Efavirenz Efavirens/Nevirapine
PI Atazanavir/ritonavir Atazanavir/ritonavir Atazanavir/ritonavir
Darunavir/ritonavir Darunavir/ritonavir Fosamprenavir/ritonavir
Fosamprenavir/ritonavir (twice daily) Fosamprenavir/ritonavir Lopinavir/ritonavir
Lopinavir/ritonavir (once or twice daily) Lopinavir/ritonavir Saquinavir/ritonavir
Saquinavir/ritonavir
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Figure 1. Virological response, CASTLE study: atazanavir/
ritonavir versus lopinavir/ritonavir in 48 and 96 weeks (ITT
analysis).
Figure 2. CASTLE: lipid changes in week 96.
Figure 3. Virological response in study KLEAN: fosamprenavir/
ritonavir versus lopinavir/ritonavir-144 weeks (ITT analysis).
Figure 4. Virological response in study ALERT: fosamprenavir/
ritonavir versus atazanavir/ritonavir in 48 weeks (ITT analysis).
Figure 5. ALERT: lipid changes in 48 weeks.
Figure 6. Virological response, study GEMINI: lopinavir/
ritonavir versus saquinavir/ritonavir in 48 weeks.
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Figure 7. Virological response in study ARTEMIS: darunavir/
ritonavir versus lopinavir/ritonavir in 48 and 96 weeks.
Figure 8. ARTEMIS: Lipidic changes in 96 weeks.
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Figure 9. Virological response in study POWER in 144 weeks.
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the investigator after being oriented by resistance tests,
associated with an optimized base therapy. As shown in Figure
9, in 144 weeks 37% of the individuals using DRV/r had a viral
load that was lower than 50 copies/mL, compared to 9% of the
patients using another PI/r. In the same analysis, the gain
with CD4 was also superior in the group treated with DRV/r.
The use of tipranavir in multi-experienced patients was
shown in RESIST studies, which included 1483 patients with
previous use of the three ARV classes, also with documented
resistance in protease. The participants were randomized to
receive tipranavir/r or one of the 4 comparator PI/r: LPV/r.
SQV/r, indinavir/r or amprenavir/r. After 48 weeks of treatment,
33.6% of the patients receiving tipranavir/r and 15.3% of those
receiving the PI/r comparator had a decrease in VL that was
higher than 1 log10 (primary study endpoint). Concerning a
VL lower than 400 copies/mL, 30.4% versus 13.8% of the
patients reached this endpoint in tipranavir/r and PI/r
comparator groups, respectively (p<0,0001) [22].
In highly active antiretroviral treatment, the ritonavir-
boosted protease inhibitors have a key role, both in naïve
patients, as well in those with antiretroviral failure, due to their
high genetic barrier and proven long term efficacy. As a initial
therapy, despite of the adverse events related to the metabolic
syndrome, it allows an efficient treatment, with low potential to
develop resistance. The virological and immune responses are
similar among the various available PI/r, as shown in randomized
clinical studies. The various PI/r options have their particularities
concerning toxicity and dosage administration, which should
be considered when choosing a PI to use, in accordance with
each clinical case. In antiretroviral rescue, even with the advent
of new classes, such as raltegravir, etravirine and maraviroque,
PI/r should still be used in therapy, according with resistant
tests, once they present a residual activity event in the presence
of mutation, besides the fact that all rescue clinical studies
highlight the importance of using this class of drugs.
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